Lantern Pharma Inc.
LTRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.24 | -0.29 | -0.37 |
| FCF Yield | -51.92% | -30.96% | -19.52% | -12.19% |
| EV / EBITDA | -1.31 | -1.56 | -1.97 | -2.91 |
| Quality | ||||
| ROIC | 0.52% | -43.45% | -25.71% | -17.51% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.90 | 0.90 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -24.09% | -12.27% | -20.63% | -87.15% |
| Safety | ||||
| Net Debt / EBITDA | 0.35 | 1.37 | 2.58 | 4.18 |
| Interest Coverage | 0.00 | 0.00 | -70.63 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.54 |
| Cash Conversion Cycle | -7,933.27 | -1,966.95 | -2,200.20 | -3,230.00 |